A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours

The goal of this phase I study was to develop a novel schedule using oral etoposide and infusional topotecan as a continually alternating schedule with potentially optimal reciprocal induction of the nontarget topoisomerase. The initial etoposide dose was 15 mg m(−2) b.i.d. days (D)1–5 weeks 1,3,5,7...

Descripción completa

Detalles Bibliográficos
Autores principales: Penson, R T, Seiden, M V, Matulonis, U A, Appleman, L J, Fuller, A F, Goodman, A, Campos, S M, Clark, J W, Roche, M, Eder, J P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361482/
https://www.ncbi.nlm.nih.gov/pubmed/15986034
http://dx.doi.org/10.1038/sj.bjc.6602671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361482/
https://www.ncbi.nlm.nih.gov/pubmed/15986034
http://dx.doi.org/10.1038/sj.bjc.6602671

Ejemplares similares